首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   268804篇
  免费   38444篇
  国内免费   2753篇
耳鼻咽喉   6663篇
儿科学   8451篇
妇产科学   4389篇
基础医学   18758篇
口腔科学   3806篇
临床医学   38103篇
内科学   71470篇
皮肤病学   9262篇
神经病学   26177篇
特种医学   10313篇
外国民族医学   4篇
外科学   57472篇
综合类   2114篇
现状与发展   73篇
一般理论   167篇
预防医学   17854篇
眼科学   6126篇
药学   9510篇
  2篇
中国医学   178篇
肿瘤学   19109篇
  2024年   725篇
  2023年   5177篇
  2022年   1957篇
  2021年   4983篇
  2020年   7049篇
  2019年   4048篇
  2018年   9457篇
  2017年   8859篇
  2016年   10062篇
  2015年   10540篇
  2014年   18486篇
  2013年   20425篇
  2012年   12916篇
  2011年   13450篇
  2010年   14664篇
  2009年   18221篇
  2008年   13444篇
  2007年   12288篇
  2006年   14520篇
  2005年   12164篇
  2004年   10977篇
  2003年   9839篇
  2002年   9498篇
  2001年   4819篇
  2000年   3800篇
  1999年   4296篇
  1998年   5185篇
  1997年   4727篇
  1996年   4393篇
  1995年   4207篇
  1994年   2809篇
  1993年   2455篇
  1992年   2054篇
  1991年   2047篇
  1990年   1673篇
  1989年   1743篇
  1988年   1548篇
  1987年   1350篇
  1986年   1374篇
  1985年   1329篇
  1984年   1357篇
  1983年   1327篇
  1982年   1657篇
  1981年   1430篇
  1980年   1292篇
  1979年   751篇
  1978年   890篇
  1977年   927篇
  1976年   674篇
  1975年   668篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
Vestibular function laboratories utilize a multitude of diagnostic instruments to evaluate a dizzy patient. Caloric irrigators, oculomotor stimuli, and rotational chairs produce a stimulus whose accuracy is required for the patient response to be accurate. Careful attention to everything from cleanliness of equipment to threshold adjustments determine on a daily basis if patient data are going to be correct and useful. Instrumentation specifications that change with time such as speed and temperature must periodically be checked using calibrated instruments.  相似文献   
6.

Background

In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).

Methods

This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.

Results

The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.

Conclusions

These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.

Plain Language Summary

  • Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
  • Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
  • Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
  • Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
  相似文献   
7.
ABSTRACT

Abortion is legal in South Africa, but negative abortion attitudes remain common and are poorly understood. We used nationally representative South African Social Attitudes Survey data to analyze abortion attitudes in the case of fetal anomaly and in the case of poverty from 2007 to 2016 (n = 20,711; ages = 16+). We measured correlations between abortion attitudes and these important predictors: religiosity, attitudes about premarital sex, attitudes about preferential hiring and promotion of women, and attitudes toward family gender roles. Abortion acceptability for poverty increased over time (b = 0.05, p < .001), but not for fetal anomaly (b = ?0.008, p = .284). Highly religious South Africans reported lower abortion acceptability in both cases (Odds Ratio (OR)anomaly = 0.85, p = .015; ORpoverty = 0.84, p = .02). Premarital sex acceptability strongly and positively predicted abortion acceptability (ORanomaly = 2.63, p < .001; ORpoverty = 2.46, p < .001). Attitudes about preferential hiring and promotion of women were not associated with abortion attitudes, but favorable attitudes about working mothers were positively associated with abortion acceptability for fetal anomaly ((ORanomaly = 1.09, p = .01; ORpoverty = 1.02, p = .641)). Results suggest negative abortion attitudes remain common in South Africa and are closely tied to religiosity, traditional ideologies about sexuality, and gender role expectations about motherhood.  相似文献   
8.
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号